87 related articles for article (PubMed ID: 15569989)
1. A pilot surrogate end point biomarker trial of perillyl alcohol in breast neoplasia.
Stearns V; Coop A; Singh B; Gallagher A; Yamauchi H; Lieberman R; Pennanen M; Trock B; Hayes DF; Ellis MJ
Clin Cancer Res; 2004 Nov; 10(22):7583-91. PubMed ID: 15569989
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of daily oral perillyl alcohol (NSC 641066) in treatment-refractory metastatic breast cancer.
Bailey HH; Attia S; Love RR; Fass T; Chappell R; Tutsch K; Harris L; Jumonville A; Hansen R; Shapiro GR; Stewart JA
Cancer Chemother Pharmacol; 2008 Jun; 62(1):149-57. PubMed ID: 17885756
[TBL] [Abstract][Full Text] [Related]
3. Novel translational model for breast cancer chemoprevention study: accrual to a presurgical intervention with tamoxifen and N-[4-hydroxyphenyl] retinamide.
Singletary E; Lieberman R; Atkinson N; Sneige N; Sahin A; Tolley S; Colchin M; Bevers T; Stelling C; Fornage B; Fritsche H; Hittelman W; Kelloff G; Lippman SM
Cancer Epidemiol Biomarkers Prev; 2000 Oct; 9(10):1087-90. PubMed ID: 11045792
[TBL] [Abstract][Full Text] [Related]
4. Phase II clinical trial of N-(4-Hydroxyphenyl)retinamide and tamoxifen administration before definitive surgery for breast neoplasia.
Singletary SE; Atkinson EN; Hoque A; Sneige N; Sahin AA; Fritsche HA; Lotan R; Lu T; Hittelman WN; Bevers TB; Stelling CB; Lippman SM
Clin Cancer Res; 2002 Sep; 8(9):2835-42. PubMed ID: 12231524
[TBL] [Abstract][Full Text] [Related]
5. Insulin-like growth factor-I inhibition with pasireotide decreases cell proliferation and increases apoptosis in pre-malignant lesions of the breast: a phase 1 proof of principle trial.
Singh B; Smith JA; Axelrod DM; Ameri P; Levitt H; Danoff A; Lesser M; de Angelis C; Illa-Bochaca I; Lubitz S; Huberman D; Darvishian F; Kleinberg DL
Breast Cancer Res; 2014 Nov; 16(6):463. PubMed ID: 25385439
[TBL] [Abstract][Full Text] [Related]
6. Phase I pharmacokinetic trial of perillyl alcohol (NSC 641066) in patients with refractory solid malignancies.
Hudes GR; Szarka CE; Adams A; Ranganathan S; McCauley RA; Weiner LM; Langer CJ; Litwin S; Yeslow G; Halberr T; Qian M; Gallo JM
Clin Cancer Res; 2000 Aug; 6(8):3071-80. PubMed ID: 10955786
[TBL] [Abstract][Full Text] [Related]
7. A pilot study to establish a clinical model to perform phase II studies of breast cancer chemopreventive agents in women at high risk with biomarkers as surrogate endpoints for activity.
Stearns V; Gallagher A; Kleer CG; Singh B; Freedman M; Haddad BR; Isaacs C; Warren R; Brown M; Cullen J; Trock B; Hayes DF
Clin Cancer Res; 2004 Dec; 10(24):8332-40. PubMed ID: 15623610
[TBL] [Abstract][Full Text] [Related]
8. Activation of the transforming growth factor beta signaling pathway and induction of cytostasis and apoptosis in mammary carcinomas treated with the anticancer agent perillyl alcohol.
Ariazi EA; Satomi Y; Ellis MJ; Haag JD; Shi W; Sattler CA; Gould MN
Cancer Res; 1999 Apr; 59(8):1917-28. PubMed ID: 10213501
[TBL] [Abstract][Full Text] [Related]
9. A pilot study of perillyl alcohol in pancreatic cancer.
Matos JM; Schmidt CM; Thomas HJ; Cummings OW; Wiebke EA; Madura JA; Patrick LJ; Crowell PL
J Surg Res; 2008 Jun; 147(2):194-9. PubMed ID: 18498869
[TBL] [Abstract][Full Text] [Related]
10. Induction of apoptosis in liver tumors by the monoterpene perillyl alcohol.
Mills JJ; Chari RS; Boyer IJ; Gould MN; Jirtle RL
Cancer Res; 1995 Mar; 55(5):979-83. PubMed ID: 7867007
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcome in patients with recurrent malignant glioma treated with Perillyl alcohol inhalation.
DA Fonseca CO; Teixeira RM; Silva JC; DE Saldanha DA Gama Fischer J; Meirelles OC; Landeiro JA; Quirico-Santos T
Anticancer Res; 2013 Dec; 33(12):5625-31. PubMed ID: 24324108
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of perillyl alcohol administered four times daily continuously.
Morgan-Meadows S; Dubey S; Gould M; Tutsch K; Marnocha R; Arzoomanin R; Alberti D; Binger K; Feierabend C; Volkman J; Ellingen S; Black S; Pomplun M; Wilding G; Bailey H
Cancer Chemother Pharmacol; 2003 Nov; 52(5):361-6. PubMed ID: 12904896
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxicity of perillyl alcohol against cancer cells is potentiated by hyperthermia.
Ahn KJ; Lee CK; Choi EK; Griffin R; Song CW; Park HJ
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):813-9. PubMed ID: 14529788
[TBL] [Abstract][Full Text] [Related]
14. A phase II breast cancer chemoprevention trial of oral alpha-difluoromethylornithine: breast tissue, imaging, and serum and urine biomarkers.
Fabian CJ; Kimler BF; Brady DA; Mayo MS; Chang CH; Ferraro JA; Zalles CM; Stanton AL; Masood S; Grizzle WE; Boyd NF; Arneson DW; Johnson KA
Clin Cancer Res; 2002 Oct; 8(10):3105-17. PubMed ID: 12374678
[TBL] [Abstract][Full Text] [Related]
15. A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer.
Stearns V; Singh B; Tsangaris T; Crawford JG; Novielli A; Ellis MJ; Isaacs C; Pennanen M; Tibery C; Farhad A; Slack R; Hayes DF
Clin Cancer Res; 2003 Jan; 9(1):124-33. PubMed ID: 12538460
[TBL] [Abstract][Full Text] [Related]
16. Lobular carcinoma in situ at percutaneous breast biopsy: surgical biopsy findings.
Liberman L; Sama M; Susnik B; Rosen PP; LaTrenta LR; Morris EA; Abramson AF; Dershaw DD
AJR Am J Roentgenol; 1999 Aug; 173(2):291-9. PubMed ID: 10430122
[TBL] [Abstract][Full Text] [Related]
17. Lapatinib activity in premalignant lesions and HER-2-positive cancer of the breast in a randomized, placebo-controlled presurgical trial.
Decensi A; Puntoni M; Pruneri G; Guerrieri-Gonzaga A; Lazzeroni M; Serrano D; Macis D; Johansson H; Pala O; Luini A; Veronesi P; Galimberti V; Dotti MC; Viale G; Bonanni B
Cancer Prev Res (Phila); 2011 Aug; 4(8):1181-9. PubMed ID: 21685235
[TBL] [Abstract][Full Text] [Related]
18. Biological response to hormonal manipulation in oestrogen receptor positive ductal carcinoma in situ of the breast.
Boland GP; McKeown A; Chan KC; Prasad R; Knox WF; Bundred NJ
Br J Cancer; 2003 Jul; 89(2):277-83. PubMed ID: 12865917
[TBL] [Abstract][Full Text] [Related]
19. Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers.
Guix M; Granja Nde M; Meszoely I; Adkins TB; Wieman BM; Frierson KE; Sanchez V; Sanders ME; Grau AM; Mayer IA; Pestano G; Shyr Y; Muthuswamy S; Calvo B; Krontiras H; Krop IE; Kelley MC; Arteaga CL
J Clin Oncol; 2008 Feb; 26(6):897-906. PubMed ID: 18180460
[TBL] [Abstract][Full Text] [Related]
20. Lobular intraepithelial neoplasia [lobular carcinoma in situ] with comedo-type necrosis: A clinicopathologic study of 18 cases.
Fadare O; Dadmanesh F; Alvarado-Cabrero I; Snyder R; Stephen Mitchell J; Tot T; Wang SA; Ghofrani M; Eusebi V; Martel M; Tavassoli FA
Am J Surg Pathol; 2006 Nov; 30(11):1445-53. PubMed ID: 17063087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
